FDA Approves Taiho Oncology's LONSURF(R) (trifluridine/tipiracil) for Adult Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

PRINCETON, N.J., Feb. 25, 2019 -- (Healthcare Sales & Marketing Network) -- Taiho Oncology, Inc. today announced that the United States Food and Drug Administration (FDA) has approved LONSURF® as a treatment for adult patients with metastatic gastric ... Biopharmaceuticals, Oncology, FDA Taiho Oncology, LONSURF, trifluridine, tipiracil, Gastric cancer

https://salesandmarketingnetwork.com/news_release_bs.html?ID=2044790

Source: HSMN NewsFeed - February 25, 2019 Category: Pharmaceuticals Source Type: news